Detect sooner and act earlier with Signatera™

Monitor cancer status to better inform treatment decisions.

How to Order

What is Signatera™?

Signatera is a highly sensitive and personalized molecular residual disease (MRD) test using circulating tumor DNA (ctDNA), custom designed for each patient to help quantify tumour burden and identify relapse earlier than standard of care tools.

How Signatera™ helps patients through their treatment

Living scan to scan can sometimes create anxiety for patients.
The question of relapse looms in the back of the mind:
Did the treatment work? Is the cancer coming back?

Through shared decision making, patients can work closely with their care team to incorporate Signatera into their treatment plan to provide additional information for confident decision making.

Listen to Brooks Bell tell her story of how she achieved peace of mind between scans using Signatera.

Hear how Trevor is taking a more proactive approach with his health through Signatera.

How do I order this test?

Important

This test must be approved by your healthcare provider prior to ordering. After purchasing the test online, a requisition form will be sent to you via email. Please print and bring or forward via email the requisition form to your healthcare provider for signature.

HOW TO ORDER
download patient packagedownload clinician package

What does Signatera™ tell me?

Individuals who have already been diagnosed with cancer (solid tumours), and are seeking answers to the following questions:

  • Is there cancer left in the body?
  • Is additional treatment beneficial?
  • Is the treatment working?

Identification and monitoring of solid tissue cancer status by analyzing the associated tumour(s).

Now it is possible detect cancer recurrence earlier than before. Tumour-informed ctDNA testing with Signatera may have clinical utility across cancer types. It helps in the adjuvant setting to detect residual disease early and assess the need for adjuvant chemotherapy personalized to each patient. Signatera can also be used to assess for minimal residual disease more accurately than current risk assessment methods; it may be used alongside CEA to detect recurrence earlier while it may still be resectable, or to reduce false positive CEA results.

Adjuvant setting

  • Use Signatera after surgery to evaluate the need for adjuvant chemotherapy
  • Personalize and help inform when to reduce treatment

Surveillance setting

  • Assess for MRD more accurately than current risk-assessment methods
  • Use Signatera alongside CEA to detect recurrence earlier while it may still be resectable, or to reduce false positive CEA results

From the time Natera receives your initial test (i.e. tissue + blood) sample, it may take up to a month for results to become available. For subsequent test (i.e., blood) samples, it may take up to a week.

Patient Stories

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, magna aliquam erat volutpat.

Contact Us

Genetic testing can seem complicated. Our team of certified genetic counsellors and client-care specialists are available to support you along the way.



To ensure we provide you with the correct information, please select your province.

map
To ensure we provide you with the correct information, please select your province.
  • British Columbia
  • Ontario
  • Alberta
  • Manitoba
  • New Brunswick
  • Newfoundland and Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon